Proton pump inhibitors induce a caspase-independent antitumor effect against human multiple myeloma

Andrea Canitano, Elisabetta Iessi, Enrico Pierluigi Spugnini, Cristina Federici, Stefano Fais

Research output: Contribution to journalArticle

Abstract

Multiple Myeloma (MM) is the second most common hematological malignancy and is responsive to a limited number of drugs. Unfortunately, to date, despite the introduction of novel drugs, no relevant increase in survival rates has been obtained. Proton pump inhibitors (PPIs) have been shown to have significant antitumor action as single agents as well as in combination with chemotherapy. This study investigates the potential anti-tumor effectiveness of two PPIs, Lansoprazole and Omeprazole, against human MM cells. We found that Lansoprazole exerts straightforward efficacy against myeloma cells, even at suboptimal concentrations (50 μM), while Omeprazole has limited cytotoxic action. The Lansoprazole anti-MM effect was mostly mediated by a caspase-independent apoptotic-like cytotoxicity, with only a secondary anti-proliferative action. This study provides clear evidence supporting the use of Lansoprazole in the strive against MM with an efficacy proven much higher than current therapeutical approaches and without reported side effects. It is however conceivable that, consistent with the results obtained in other human tumors, Lansoprazole may well be combined with existing anti-myeloma therapies with the aim to improve the low level of efficacy of the current strategies.

Original languageEnglish
Pages (from-to)278-283
Number of pages6
JournalCancer Letters
Volume376
Issue number2
DOIs
Publication statusPublished - Jul 1 2016

Keywords

  • Apoptosis
  • Cancer
  • Hematological malignancy
  • Lanzoprazole
  • Omeprazole

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Proton pump inhibitors induce a caspase-independent antitumor effect against human multiple myeloma'. Together they form a unique fingerprint.

  • Cite this